Inventiva (IVA) Receivables - Accured (2022 - 2025)

Inventiva (IVA) posted quarterly Receivables - Accured of $14.9 billion for Q2 2025, up 17367947.13% quarter-over-quarter from $86025.0 in Q2 2023.

Inventiva (IVA) Receivables - Accured (2022 - 2025) Analysis & Trends

Inventiva's Receivables - Accured history runs 3 years deep, the most recent figure standing at $14.9 billion for Q2 2025.

In Q2 2025, Receivables - Accured changed N/A year-over-year to $14.9 billion; the TTM figure through Jun 2025 stood at $14.9 billion (changed N/A YoY), while the FY2022 annual figure was $66316.1, changed N/A from the prior year.
Receivables - Accured for Q2 2025 stood at $14.9 billion, up from $86025.0 in the prior quarter.
The five-year high for Receivables - Accured was $14.9 billion in Q2 2025, with the low at $66316.1 in Q4 2022.
The 3-year median for Receivables - Accured is $86025.0 (2023), against an average of $5.0 billion.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acc. Int. Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Inventiva	888.89 Mn	888.89 Mn	-	-

Download Data